Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients

ClinicalTrials.gov ID: NCT01199939

Public ClinicalTrials.gov record NCT01199939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Single Arm, Open-Label Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is a Phase II single arm, open-label, multicenter, study of 50 human immunodeficiency virus-1 (HIV) infected adult patients, all of whom will receive etravirine (ETR) 400mg and DRV/r 800/100mg each given orally once daily. This trial is designed to evaluate the efficacy of the aforementioned ARV regimen, as measured by the percentage of patients with HIV RNA \<50 copies/mL at 48 weeks, in early treatment-experienced HIV-infected patients. In addition to general safety parameter measurements, this trial will also assess changes in metabolic, inflammatory, immune restoration, and bone markers. Screening will occur over a 6-week period. The primary endpoint will be assessed at Week 48, and the treatment period is 48 weeks. The end of study endpoint will be met by either completing the Week 48 visit, or by early termination from the study for any reason.

Study identification

NCT ID
NCT01199939
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Tibotec, Inc
Industry
Enrollment
54 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2010 (Type not available)
Primary completion
Oct 2012 (Actual)
Completion
Oct 2012 (Actual)
Last update posted
Dec 4, 2013

2010 – 2012

United States locations

U.S. sites
22
U.S. states
12
U.S. cities
22
Facility City State ZIP Site status
Not listed Long Beach California — —
Not listed Los Angeles California — —
Not listed San Francisco California — —
Not listed Denver Colorado — —
Not listed Washington D.C. District of Columbia — —
Not listed Ft. Pierce Florida — —
Not listed Miami Florida — —
Not listed Orlando Florida — —
Not listed Decatur Georgia — —
Not listed Macon Georgia — —
Not listed Berkley Michigan — —
Not listed St Louis Missouri — —
Not listed Hillsborough New Jersey — —
Not listed Neptune City New Jersey — —
Not listed Buffalo New York — —
Not listed Manhasset New York — —
Not listed Charlotte North Carolina — —
Not listed Austin Texas — —
Not listed Dallas Texas — —
Not listed Harlingen Texas — —
Not listed Houston Texas — —
Not listed Seattle Washington — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01199939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 4, 2013 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01199939 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →